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INTRODUCTION  
1,3,4-Thiadiazole are important because of their versatile biological actions. They have extensive applications as 
structural units of various biologically important molecules and as useful intermediates in medicinal chemistry. It is well 

























































and anti HIV 
[159]
. 
 Many reviews have been published regarding the chemistry of this compound the synthetic versatility of 
thiadiazoles has stemmed from the interest in the biological and pharmacological properties of its derivatives. These 
properties are more fully detailed in the supplementary material. The review compiles published data on the synthesis and 
biological action of new thiadiazole derivatives until 2012.  
SYNTHESIS OF 1,3,4-THIADIAZOLES AND FUSED 1,3,4-THIADIAZOLES 
1) From thiosemicarbazide 
a-With nitriles 
The reaction of thiosemicarbazide 1 with benzonitrile in the presence of trifluoroacetic acid afforded 2-amino-5-
phenyl-1,3,4-thiadiazole 3 through the formation of the intermediate 2 which indicates the hydrolysis of benzonitrile 
followed by condensation with thiosemicarbazide and finally undergoes intramolecular cyclization 
[160]




















The synthesis of 2-(1-methyl-5-nitro-1H-2-imidazol- yl)-5-substituted-1,3,4-thiadiazoles 7a-g was achieved 
[161]
 




































7a : X = CH2
7b : X = O
7c : X = NH
7d : X = NMe
7e : X = NPh
7f : X = NCOMe




Scheme 2. Synthetic pathway to compounds 7a-g 
b-With acid anhydride and acid chloride 
  Stirring thiosemicarbazide with trifluoroacetic anhydride at -5°C for 2h yielded 2-amino-5-trifluoro-methyl-1,3,4-
thiadiazole 8 (81%) 
[162]
. 
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Acylation of thiosemicarbazide with acid chloride 10 and 11 in the presence of pyridine afforded compounds 12 
and 13
 


































10 : n = 2
11 : n = 3
12 : n = 2
13 : n = 3
H2SO4
14 : n = 2




c-With acid in presence of POCl3 
 The fact that 2,5-disubstituted-1,3,4-thiadiazole derivatives [37-39] and 5-nitro-2-imidazolyl analogues (e.g. 
metronidazole) 
[40,41]
 have antibacterial activity, a new series of N-substituted piperazinyl quinolinones carrying a 5-(1-
methyl-5-nitro-2-imidazolyl)-1,3,4-thiadiazole moiety 19a-c were designed and synthesized as potential antibacterial 
agents. Also, some N-[5-(nitropheny1)-1,3,4-thiadiazol-2-yl]piperazinyl quinolones 19 were synthesized for their 
antibacterial activity 
[165]

































18a : X = CH, R =
18b : X = CH, R =Et








a : Ar =
b : Ar =
c : Ar =
d : Ar =
 
Scheme 4 
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 The formation of 1,3,4-thiadiazole derivative 21 by the reaction between 1,2-benzisoxazole-3-acetic acid 20 and 
thiosemicarbazide 
[166]
. 2-Amino-5-benzo[d]isooxazol-3-ylmethyl-[1,3,4]thiadiazole 21 upon condensation with α-haloaryl 
ketones yielded the imidazothiadiazoles 22. It is well established that this reaction proceeds via the intermediate 
iminothiadiazole 
[18]
 which under reflux temperature spontaneously undergoes dehydrocyclisation to form the desired 
fused heterocycle. The electronic and steric factors at 5
th
 position of 2-amino-5- substituted-1,3,4-thiadiazole are crucial in 
determining the course of its reaction with substituted α-haloarylketones. The strongly electronegative groups imparts less 
nucleophilic character to the nitrogen at 4
th


































 The compound 23 were employed as starting material for synthesis of new 1,3,4-thiadiazole-2-arylhydrazone 
derivatives 
[167]


















Cu°, 12N aq. HCl




























Scheme 6. Synthetic route for the preparation of the new 1,3,4-thiadiazole-2-arylhydrazone derivatives 26. 
 2-Amino-5-(3,4,5-trimethoxypheny1)-1,3,4-thiadiazole 27 was obtained by direct cyclisation of 3,4,5-trimethoxy 
benzoic acid and thiosemicarbazide in the presence of phosphorus oxychloride, the latter refluxed with substituted α-
haloaryl ketones in dry ethanol yielded the imidazothiadiazoles 
[168]
 28.  
 Vilsmeier-Haack reaction of imidazothiadiazoles 28 in dimethylformamide and phosphorus oxychloride provided 
6-aryl-2-(3,4,5-trimethoxyphenyl)imidazo[2,1-b][1,3,4]thiadiazole-5-carboxaldehyde derivatives 29 which subjected to 
Knoevenagel condensation with 2,4-thiazolidinedione in the presence of catalytic amount of piperidine and acetic acid to 
afford 5-substituted-2,4-thiazolidinediones 
[168]
 30. (Scheme 7) 
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Scheme 7. Reagents a) POCl3; b) dry ethanol, 10h; c)Vilsmeier-H, 10h, 85-   92%; d) thiazolidin-2,4-dione, piperidine, 
acetic acid, toluene. 
Compounds of the general structure 33 were prepared 
[169-175]
 by (i) reaction of carboxylic acid 31 with a 
hydrazide compound in the presence of coupling reagents (EDCI, DMAP) and (ii) thionation-cyclization of the resulting 
product 32 using Lawesson's reagent 
[176]
. Alternatively, the acylhydrazide intermediate 32 was also available through the 
coupling of the hydrazide 35 with a corresponding acid 36 mediated by coupling reagents such as DMAP, EDCI or EDCI, 
HOBt, NMM. For this sequence, the requisite hydrazide 35 was prepared by treating the known ester 34 with hydrazine in 
refluxing EtOH 
[177]




























































Scheme 8. Preparation of thiadiazole 33. 
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The preparation of thiadiazole 39 was initiated with the activated 4-pyrazole intermediate 38, which was prepared 
from 37 via a benzylic bromination-type reaction
 [178-182]
 as illustrated in (Scheme 9). The triazole group of 39 was then 































Scheme 9. Preparation of thiadiazole 39. 
The thiadiazole containing the 1,2,4-triazole could also be obtained by a reaction sequence involving the key 
intermediate bromide 40. Thus, bromide
 
40 obtained by reaction of pyrazole 34 with NBS in the presence of catalytic 
AIBN, was reacted with 1,2,4-triazole sodium derivatives to provide 41. Hydrazinolysis of ester 41 produced the 
corresponding hydrazide 42, which could then be coupled with an acid to give acyl hydrazide 43. Alternatively, hydrolysis 
of ester 41 and activation of the acid followed by coupling with a hydrazide in the presence of triethyl amine then afforded 
acyl hydrazide 43. Thionation-cyclization was then performed using Lawesson's reagent under microwave irradiation to 
give thiadiazole 
[177]







































































Scheme 10. Preparation of thiadiazole 39. Reagents and conditions: a) NBS, AIBN, CCl4; b)1,2,4-triazole.Na, DMF; c) 
hydrazine.H2O, EtOH, 65ºC; d) pivalic acid, EDCl, HOBt, NMM, DMF; e) Lawesson's reagent, THF, reflux or microwave. 
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The microwave assisted reaction between 5-(trifluoromethyl)-1,3,4-thiadiazol-2-amine 8 and various substituted 
α-haloaryl ketone. In the next step, imidazo[2,1-b][1,3,4]-thiadiazoles 44 were subjected in to Vilsmeier-Haack reaction to 
afford 2-(trifluoromethyl)-6-arylimidazo [2,1-b][1,3,4]-thiadiazole-5-carbaldehydes 45 which subjected to Knoevenagel 
condensation 
[183,184]
 with thiazolidine-2,4-dione, 2-thioxothiazolidin-4-one (rhodanine) and 2-(4-oxo-2-thioxothiazolidin-3-
yl)acetic acid (rhodanine acetic acid) in the presence of catalytic amount of piperidine acetate to afford 6-arylimidazo[2,1-





















































































Scheme 11. Reagents and conditions: a) -5 to 0ºC, 2h, 81%; b)M.W. (600 watts) 10-15 min, 65-71%; c) Vilsmeiere-Haack 
reagent, 8h, 50-66%; d) thiazolidine-2,4-dione, M.W. (600 watts) 10 min, 69-72%; e) rhodanine, M.W. (600 watts) 12 min, 
69-75%; f) rhodanine acetic acid, M.W. (600 watts) 12 min, 68-76%. 
d-With aldehydes 
 Another regioisomer, 5-amino-[1,3,4]thiadiazole derivatives 50 was prepared from the reaction of p-anisaldehyde 
with thiosemicarbazide to give intermediate 49, followed by cyclization in the presence of ferric chloride in aqueous 
solution 
[185,186]
. (Scheme 12) 
Aminothiadiazole 50 was subjected in the standard acylation protocols including coupling reagents with acids or 
anhydride or acid chloride with pyridine as base to afford 51. (Scheme 12) 
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 1-Methyl-5-nitroimidazole-5-carboxaldehyde [53,187-190] 52 upon treatment with thiosemicarbazide yielded the 
corresponding thiosemicarbazone which cyclized with ammonium ferric sulphate to give the thiadiazole derivative 53.
 
Diazotization of amine 53 followed by reaction with piperazine afforded 55 which with aroyl chloride gave N-aroylation 
1,3,4-thiadiazole derivative 
[191-194]










































a : R = phenyl                  e : R = thiophen-2-yl
b : R = 2-Cl-phenyl          f : R =5-Cl-thiophen-2-yl
c : R = 3-Cl-phenyl          g : R =5-Br-thiophen-2-yl
d : R = 4-Cl-phenyl  
Scheme 13. Reagents and conditions: i) thiosemicarbazide, EtOH, HCl, reflux; ii) ammonium ferric sulfate, H2O, reflux; iii) 
NaNO2, HCl, Cu; iv) piperazine, EtOH, reflux; v) appropriate thiophen-2-carbonyl chlorides or benzoyl chlorides, benzene, 
pyridine, rt. 
  Thiosemicarbazones of substituted quinoline 59 were prepared and cyclized in presence of acetic anhydride to 
get the final thiadiazole 60 
[195]






































Scheme 14. Schematic Representation of the Synthetic route adopted for the synthesis N-4-acetyl-5-(2,8-
substitutedquinolin-3-yl)4,5-dihydro1,3,4-thiadiazole-2-yl)acetamide derivative 60. 
3-(1,3,4-Thiadiazoly1)-2-styryl-quinazoline-4(3H)-one 65 was synthesized by a three-step procedure 
[196]
. (Scheme 15)  
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Scheme 15. Synthesis of 3-(1,3,4-thiadiazolyl)-2-styryl quinazolin-4(3H)one 65. 
The 2-amino-5-(5-nitro-2-thienyl)-1,3,4-thiadiazole 67 was obtained by oxidative cyclization of 5-nitro-2-thiophene 
carboxaldehyde thiosemicarbazone 66. Diazotation of 67 in hydrochloric acid in the presence of copper powder gave 2-




Treatment of the latter with alkyl chloroacetates gave alkyl-α-[5(5-nitro-2-thienyl)1,3,4-thiadiazole-2-yl thio] 
acetates 70 
[197]
. (Scheme 16) 
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Scheme 16. Synthesis of alkyl α-[5-(5-nitro-2-thienyl)-1,3,4-thiadiazole-2-yl thio]acetates 70. 












 and antiulcer activities
 [106,107]
. The treatment of 3-aryl-4-formylsydnone 4'-
phenylthiosemicarbazones 71 with acetic anhydride in dichloromethane solution, following by heating at 75°C in an oil 
bath for 18-20h, produced the monoacetyl sydnonyl 1,3,4-thiadiazoline derivatives 72 and heating for a longer period the 
monoacetyl completely converted to the diacetyl substituted thiadiazolines 73 
[198]
. (Scheme 17) 
However, treating 71 with acetic anhydride without any other solvent produced the diacetyl-substituted 
thiadiazolines
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Scheme 19. The mechanism of reaction of compounds 71 with ferric chloride. 
e-With carbon disulphide 
It has been shown earlier by Supuran et al. that thiol carrying heterocycles can lead to the development of novel 
types of carbonic anhydrase inhibitors. 
[199-202]
 However the previously investigated heterocyclic thiols showed moderate 
inhibitory activities with no preferential inhibition against the tumor-associated isozyme CAIX.
[203]
 Considering the 5-amino-
3H-1,3,4-thiadiazole-2-thione 75 system as a scaffold. New class of semicarbazone derivatives of such system were 
synthesized and tested against the cytosolic as well as the tumor-associated CA isozymes I, II, and IX.  
[1,3,4]Thiadiazoles 75-78 were synthesized using the reported Cho et al. method 
[204]
 via the reaction between 
thiosemicarbazide and carbon disulfide in alkaline medium to give the key intermediate 77 
[205-212]
. (Scheme 20) 
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Scheme 20. Synthetic pathway of for intermediates 75-77 and target compounds 78, 79. Reagents and conditions: i) 
KOH, ethanol, reflux 6h; ii) ClCOOC2H5 / pyridine, stir 1h below 40 ºC; iii) hydrazine hydrate 80%, 60 ºC (1h), stir 48h at 
room temperature; iv) ethanol, reflux 1h, stir overnight; v) ethanol, reflux 3-5h, refrigerate overnight. 
 
2) From Acid hydrazide 
i-With Aryl isothiocyanate 



































Scheme 21. Synthesis of 5-arylamino-1,3,4-thiadiazol-2-yl-acetamides 82. 
 Treatment of hydrazide 85 with various alkyl/aryl isothiocyanates in ethanol gave corresponding 
thiosemicarbazides 86. Cyclization of 86 by treating with cold concentrated sulphuric acid gave the 1,3,4-thiadiazole 87. 
[90]
 (Scheme 22) 
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The synthetic route for the newly synthesized, 1,3,4-thiadiazole derivatives 95, is illustrated. 
[80,155,214-220]


















































Scheme 23. Synthesis of  1,3,4-thiadiazole derivatives. a) dry methanol, conc. H2SO4, reflux; b) dry methanol, hydrazine 
hydrate 80%, reflux; c) CS2, NH4OH 33%, dry methanol; d) Pb(NO3)2; e) dry methanol, reflux; f) 4N NaOH, reflux; g) PPA, 
stirring. 
The interaction of ethyl thioglycolate with 3-chloroacrylaldehydes 
[221]
 96 in pyridine in the presence of 
triethylamine led to ethyl thiophene-2-carboxylates 97 
[222]
. 
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 Hydrazinolysis of 98 followed by reaction with ethyl isothiocyanate then cyclization using sulfuric acid afforded 
N-ethy1-5-substituted-1,3,4-thiadiazol-2-amines  100
 [223]






































Scheme 24. Synthesis of 1,3,4-thiadiazole derivatives. Reagents and conditions: a) DMF, POCl3, trichloroethylene; b) 
thioglycolate, triethylamine, pyridine, 10-15 ºC; c) hydrazine hydrate, ethanol, reflux; d) ethyl isothiocyanate, ethanol, 
reflux; e) concentrated sulfuric acid, 0 ºC. 
A series of 1,3,4-thiadiazoles 104 were prepared 
[224]










































Scheme 25. Reagents: i) NH2NH2.H2O; ii) R1N=C=S; iii) H2SO4. 
The synthesis 1,3,4-thiadiazoles 107 
[225,226]
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ii- With CS2 
The starting 4-amino-5-(3-chloropheny1)-4H-1,2,4-triazole-3-thiol 115 was obtained in two steps. First, 3-
chlorobenzohydrazide 113 reacted with carbon disulphide in the presence of KOH to form potassium 3-chlorobenzyl 
dithiocarbamate 114. A cyclization reaction between hydrazine hydrate and 114 gave 4-amino-5-(3-chlorophenyl)-4H-
[1,2,4]-triazole-3-thiol 115.  
The compounds 117 were synthesized by reacting 4-amino-5-(3-chlorophenyl)-4H-1,2,4-triazole-3-thiol 115 with 
different aryl aldehydes in the presence of a catalytic amount of p-TsOH in dry DMF. 
[228]










































Scheme 28. Synthesis of 1,3,4-thiadiazoles 117. 
Adamantyl-1,3,4-thiadiazoles 120-122 were obtained via the reaction of hydrazide 118 with CS2/KOH 
[229]
. (Scheme 29)  
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Scheme 29. Synthesis of compounds 121 and 122. 
Moreover, the reaction of compound 120 with ethyl bromoacetate, ±-ethyl 2-bromopropionate or ethyl 3-
bromopropionate, in ethanol, in the presence of anhydrous potassium carbonate yielded the corresponding ethyl esters 















































Scheme 30. Synthesis of [1,3,4]thiadiazole derivatives 120-128. 
5-(1-Adamanty1)-2-amino-1,3,4-thiadiazole 130 was previously prepared in 48% yield from adamantane-l-
carboxylic acid hydrazide 118 via reaction with potassium thiocyanate and hydrochloric acid to yield 1-(1-adamantyl 
carbony1)-3-thiosemicarbazide 129, followed by dehydrative cyclization with sulphuric acid at room temperature. 
Compound 130 was also prepared in 59% yield via one-step three-component reaction of adamantane-1-carboxylic acid 
137, thiosemicarbazide and phosphorus oxychloride. 
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Compound 130 was reacted with phenyl-, 4-fluorphenyl- or 4-chlorophenylisothiocyanate to yield the 
corresponding N-[5-(1-adamanty1)-1,3,4-thiadiazol-2-y1]-N'-arylthioureas 132a-c in poor yields. 5-(1-Adamanty1)-1,3,4-
thiadiazoline-2-one 133 was prepared through deamination of compound 130 via treatment with sodium nitrite in cold 
aqueous hydrochloric acid solution followed by boiling for 10 min. 
[229]
 (Scheme 31) 
O





































Scheme 31. Synthesis of 1,3,4-thiadiazole 130-133. 
1,2,3-Triazolyl-s-triazolo[3,4-b]-1,3,4-thiadiazole 137 was obtained via a series of reactions involves the formation 
of the hydrazide 
[30,230-232]
 134 which treated with CS2/KOH followed by hydrazinolysis and treatment with formic acid in the 
presence of POCl3 
[233]









































The synthetic route designed for the sulfone analogues 143 is summarized in (Scheme 33). Following the re-
ported method, 
[234]
 5-(3,4,5-trimethoxypheny1)-1,3,4-thiadiazole-2-thiol 141 was synthesized from gallic acid in five steps: 
etherification, esterification, hydrazidation, salt formation, and cyclization. Phenylhydrazid 140, potassium hydroxide, and 
carbon disulfide in absolute ethanol under reflux condition. Then, 5-(3,4,5-trimethoxypheny1)-1,3,4-thiadiazole-2-thiol 141 
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were converted to thioether derivatives containing thiadiazole 142 which when treated with ammonium molybdate in ionic 













































d (1) e; (2) f
i K
 
Scheme 33. Synthetic rout to title compounds 143. Reagents and conditions: a) (CH3)2SO4, 10% NaOH; b) 35% HCl; c) 
CH3OH, 98% H2SO4, reflux; d) NH2NH2.H2O, CH3OH, reflux 5h; e) KOH, CS2, C2H5OH, rt; f) 98% H2SO4, 0-5 ºC; i) In, 3% 
NaOH, H2O, RX (6), rt; k) 30% H2O2, (NH4)6Mo7O24 (1 mol%), ionic liquid, 40 ºC, 2h. 
3) From Enaminones 
 Enaminones are polydentate reagents that have been utilized extensively in this decade as building blocks are 
organic synthesis 
[235-241]
. A new series of thiadiazole-enaminones 147 were synthesized via reactions of 5-acetyl 1,3,4-










































Scheme 34. Synthesis of enaminones 147. 
Reaction of enaminone 147 with hydrazine hydrate led to formation of the thiadiazole pyrazole linked product 148.  
In a related manner, reaction of enaminone 147 with hydroxylamine hydrochloride in the presence of potassium 
carbonate led to formation of the thiadiazole isoxazole 
[242]
 149. (Scheme 35) 
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Scheme 35. Reaction of enaminone 147 with hydrazine hydrate and hydroxylamine. 
Compound 147 reacts with active methylene compounds and yielded the regioisomeric linked thiadiazole pyridine 
structures represented by either 151 or 153. Two pathways are outlined in (Scheme 36) for this reaction. The reaction 
may proceed by initial Michael addition (route A) of the active methylene compound to the activated double bond of 147 
 to give the Michael adduct 150 followed by tandem elimination of dimethylamine and condensation with ammonia 
to give product or the other suggested pathway (route B) may proceed by initial condensation of active methylene 
compound with the carbonyl group of 147 which leads to formation of intermediate 152 that cyclizes in the presence of 



























































Scheme 36. Reaction of enaminone 147 with active methylene compounds. 
Also, the reactivity of the enaminone 147 towards some heterocyclic amines was examined. For example, 5-
amino-1,2,4-triazole was found to react with 147 in acetic acid to yield the 1,2,4-triazolo[1,5-a] pyrimidine derivative 154 
(Scheme 37). Similarly, treatment of 147 with each of 2-aminobenzimidazole and 5-amino-3-phenylpyrazole under the 
same reaction conditions afforded the respective benzimidazo[1,2-a]pyrimidine
 
155 and pyrazolo[1,5-a] pyrimidine  
derivatives 
[242]
 156. (Scheme 37) 
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Scheme 38. The mechanism of reaction of enaminone 147 with heterocyclic amine. 
 
 
    ISSN 2321-807X 
2832 | P a g e                                                      O c t o b e r  0 2 ,  2 0 1 4  
4) From Hydrazonyl halides 
 2,3-Dihydro-1,3,4-thiadiazole derivative containing coumarin moieties were synthesized from the reactions of 
methyl (or benzyl) carbodithioate with C-coumarinoyl-N-phenyl hydrazonoyl bromide 
[243]












































Furthermore, 2,3-dihydro-1,3,4-thiadiazoles containing pyrazole moieties were prepared from the reaction of 
alkyl-2-[1-(4-cyano-1,5-diphenyl-1H-pyrazol-3-yl)ethylidene]-hydrazine carbodithioate with appropriate hydrazonyl halides. 
[244]
 (Scheme 40,41) 
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R = 5-phenyl-1-p-tolyl-1H-pyrazolyl-4-carbonitrile  
Scheme 41 
The ambient nucleophilic centers present in 3-substituted-4-amino-5-mercapto-1,2,4-triazoles render them as 
useful synthons for the synthesis of various N-bridged heterocycles. The key intermediates, 4-amino-5-[4-(4-X-
phenylsulfonyl) phenyl]-4H-1,2,4-triazole-3-thiols 175 (X= H, Br) were prepared from corresponding substituted benzoic 
acid hydrazides according to literature 
[245]
. The resulted triazoles 175 further converted to 3-[4-(4-X-phenylsulfonyl) 
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pheny1]-6-N-(substituted phenyl) amino-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole
 
176-178 by reacting with different reagents 
[246]











































i- aromatic isothiocyanate / DMF / reflux
ii- aromatic acid / POCl3 / reflux
iii- urea, fusion, 250C
iv- CDI / dioxane
(175)
 
Scheme 42. Synthesis of 1,2,4-triazolothiadiazoles 176-178. 
Cyclocondensation of the SH and NH2 functions of 175 with various substituted aromatic acids in the presence of 
phosphorus oxychloride afforded a series of 3-[4-(4-X-phenylsulfonyl)pheny1]-6-(substituted phenyl)-[1,2,4]triazolo[3,4-b] 
[1,3,4]thiadiazoles 177. The ring closure reaction with POC13 as the cyclization may have an esterification-addition-
elimination mechanism 
[246]















































5) From Oxamic acid thiohydrazide 
Oxamic acid thiohydrazides 178 and aldehydes, gave the corresponding hydrazones 179, based on 
which the previously undescribed 4,5-dihydro-1,3,4-thiadiazole-2-carboxamides 180 and 2-carbamoy1-4,5-dihydro-1,3,4-
thiadiazole-1-oxides 182 
[247]
 were obtained. (Scheme 44) 
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6) From 3-Substituted amino quinazolin-4(3H)one 
Derivatives of 3-aminoquinazolin-4(3H)-one are widely used in organic synthesis and exhibit a wide spectrum of 
physiological properties 
[248-250]
. Heating of 3-N,N-dimethylthioureidoquinazolin-4(3H)-one 183 with concentrated sulfuric 
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